WP2VALUE ASSESSMENT IN HEALTH TECHNOLOGY

Lead partner
LSE


Type of activity
Research


Core research objectives

  1. To understand the parameters of value in HTA appraisals from an international perspective/
  2. To explore how factors such as disease severity, burden of disease, distinguishing between levels of innovation, and the quality of the available evidence can be incorporated more explicitly – and in a quantifiable way, in the HTA process.
  3. To explore how alternative analytical frameworks, such as Multi-criteria Decision Analysis (MCDA), can be used to elicit value.
  4. To conduct case studies in specific disease areas by using alternative analytical tools and by explicitly incorporating all identified parameters of value.

During the first two years of the project, WP2 has completed the following tasks:

  • Systematic review of the Health Technology Assessment (HTA) literature, enabling the understanding of:
    • The value assessment processes across different jurisdictions.
    • The differences across jurisdictions, recognising their likely advantages and limitations.
    • The value dimensions incorporated in the overall assessment process and how are they used in different settings.
  • Development of an alternative methodological framework of value assessment using Multiple Criteria Decision Analysis (MCDA) with the following characteristics:
    • Feeding from a more holistic definition of value that takes into account more explicitly a wider set of dimensions and their relative importance.
    • Using a clear, transparent and comprehensive set of criteria for assessing the performance of alternative medical technologies.
    • Addressing the main limitations of the cost per QALY metric, while capturing a link between value and HTA decision in order to achieve efficient allocation of resources.
  • Development and empirical testing of an analytical framework that enables the systematic comparison of HTA decisions across drugs, therapeutic areas, and countries, through:
    • understanding of these complex decision processes
    • comparing how these have been conducted in different countries for the same drug and indication pairs
    • learning from other country experiences and highlights areas where the debate around HTA methodological approaches can be furthered.

During third and final year of the project, WP2 has completed the following tasks:

  • Applied the MCDA value assessment framework through a series of disease-specific case studies.
  • Analysed a larger sample of cancer and central nervous system treatments through the developed analytical framework.

Summary of conclusions
A comparative analysis of four countries in assessing orphan drugs

Using Multiple Criteria Decision Analysis (MCDA) in the context of HTA: an experimental case study on metastatic colorectal cancer


Principal Investigator: Dr Panos Kanavos

Acronym ADVANCE_HTA
Full title Advancing and strengthening the methodological tools and policies relating to the application and implementation of Health Technology Assessment (HTA)
Project number 305983
CoordinationLSE Health
Consortium 13 partners

The research leading to these results has received funding from the European Community's Seventh Framework Programme FP7/2007-2013 under grant agreement No. 305983.